__NUXT_JSONP__("/drugs/Trametinib", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:b,conditionIndication:"MelanomaTrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy (see section 5.1).Adjuvant treatment of melanomaTrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.Non-small cell lung cancer (NSCLC)Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.Â ",inn:b,marketingAuthorisationDate:"2014-06-30 00:00:00",marketingAuthorisationHolder:"Novartis Europharm Limited",medicineName:"Mekinist",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fmekinist"}],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"871700-17-3",chebiId:"",chemicalFormula:"C26H23FIN5O4",definition:"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK\u002FERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine\u002Fthreonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS\u002FRAF\u002FMEK\u002FERK signaling pathway that regulates cell growth.",fdaUniiCode:"33E86K87QN",identifier:"C77908",preferredName:a,semanticType:"Organic Chemical",subclassOf:["C129825","C69145"],synonyms:["GSK1120212","JTP-74057","MEK Inhibitor GSK1120212","N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide","TRAMETINIB",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FTrametinib",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Trametinib","trametinib","2021-10-30T13:45:01.163Z")));